Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy

As part of a clinical trial investigating the level of nicotine replacement with different doses of transdermal therapy for smoking cessation, peak and trough serum nicotine and plasma cotinine concentrations were measured in 70 subjects while they were actively smoking (baseline) and daily for 6 consecutive inpatient days while they were receiving transdermal nicotine. Subjects were randomly assigned to a daily 24-hour patch delivering a transdermal nicotine dose of 0, 11, 22, or 44 mg and stratified by self-reported smoking rate as either light (10-15 cigarettes per day), moderate (16-30 cigarettes per day), or heavy (>30 cigarettes per day). Steady-state concentrations of nicotine and cotinine were attained in 1 and 3 days, respectively, at all doses and were independent of baseline smoking rate. Mean percentage replacement of nicotine was calculated by dividing steady-state peak nicotine or cotinine concentrations by their respective baseline concentrations. Significant underreplacement occurred in subjects receiving the 11 mg/day patch regardless of baseline smoking rate. Underreplacement also occurred in moderate and heavy smokers receiving 22 mg/day and in light smokers at this same dose. Complete replacement occurred only in subjects receiving the 44 mg/day patch. These results have several implications for transdermal nicotine therapy. First, with the higher nicotine and cotinine levels observed with heavier smoking, it is inherent that one size does not fit all, and there is a need to consider more individualization of dosage for nicotine patch therapy. Second, there is substantial underreplacement with the 22 mg/day dose in moderate to heavy smokers and in some light smokers. Third, even with twice the usual dose (i.e., 44 mg/day), there was no accumulation of either nicotine or cotinine. Plasma cotinine levels after achievement of steady state (i.e., after 3 days of patch therapy) can be collected at any time and used to calculate percent replacement using baseline levels.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. E. Hong, M. Schroeder, T. J. Ross, B. Buchholz, B. J. Salmeron, I. Wonodi, G. K. Thaker, and E. A. Stein Nicotine Enhances but Does Not Normalize Visual Sustained Attention and the Associated Brain Network in Schizophrenia Schizophr Bull, August 27, 2009; (2009) sbp089v1. [Abstract] [Full Text] [PDF]

				H. A. N. Al-Wadei, H. K. Plummer III, and H. M. Schuller Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter {gamma}-aminobutyric acid Carcinogenesis, March 1, 2009; 30(3): 506 - 511. [Abstract] [Full Text] [PDF]

				P. V. Dicpinigaitis, B. Sitkauskiene, K. Stravinskaite, D. W. Appel, A. Negassa, and R. Sakalauskas Effect of smoking cessation on cough reflex sensitivity Eur. Respir. J., October 1, 2006; 28(4): 786 - 790. [Abstract] [Full Text] [PDF]

				P. P. Lau, L. Li, A. J. Merched, A. L. Zhang, K. W.S. Ko, and L. Chan Nicotine Induces Proinflammatory Responses in Macrophages and the Aorta Leading to Acceleration of Atherosclerosis in Low-Density Lipoprotein Receptor-/- Mice Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 143 - 149. [Abstract] [Full Text] [PDF]

				S. Sobue, K. Sekiguchi, H. Kikkawa, and S. Irie Effect of Application Sites and Multiple Doses on Nicotine Pharmacokinetics in Healthy Male Japanese Smokers Following Application of the Transdermal Nicotine Patch J. Clin. Pharmacol., December 1, 2005; 45(12): 1391 - 1399. [Abstract] [Full Text] [PDF]

				X. Xu, M. M. Iba, and C. P. Weisel Simultaneous and Sensitive Measurement of Anabasine, Nicotine, and Nicotine Metabolites in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., December 1, 2004; 50(12): 2323 - 2330. [Abstract] [Full Text] [PDF]

				T. T. Lang, J. D. Young, and C. E. Cass Interactions of Nucleoside Analogs, Caffeine, and Nicotine with Human Concentrative Nucleoside Transporters 1 and 2 Stably Produced in a Transport-Defective Human Cell Line Mol. Pharmacol., April 1, 2004; 65(4): 925 - 933. [Abstract] [Full Text]

				C. Lerman, V. Kaufmann, M. Rukstalis, F. Patterson, K. Perkins, J. Audrain-McGovern, and N. Benowitz Individualizing Nicotine Replacement Therapy for the Treatment of Tobacco Dependence: A Randomized Trial Ann Intern Med, March 16, 2004; 140(6): 426 - 433. [Abstract] [Full Text] [PDF]

				P. Jatlow, S. McKee, and S. S. O'Malley Correction of Urine Cotinine Concentrations for Creatinine Excretion: Is It Useful? Clin. Chem., November 1, 2003; 49(11): 1932 - 1934. [Full Text] [PDF]

				T. P. Moyer, J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles Clin. Chem., September 1, 2002; 48(9): 1460 - 1471. [Abstract] [Full Text] [PDF]

				J. B.Mailhes, D. Young, G. Caldito, and S.N. London Sensitivity of mouse oocytes to nicotine-induced perturbations during oocyte meiotic maturation and aneuploidy in vivo and in vitro Mol. Hum. Reprod., March 1, 2000; 6(3): 232 - 237. [Abstract] [Full Text] [PDF]

				R. D. Hurt, G. A. Croghan, S. D. Beede, T. D. Wolter, I. T. Croghan, and C. A. Patten Nicotine Patch Therapy in 101 Adolescent Smokers: Efficacy, Withdrawal Symptom Relief, and Carbon Monoxide and Plasma Cotinine Levels Arch Pediatr Adolesc Med, January 1, 2000; 154(1): 31 - 37. [Abstract] [Full Text] [PDF]